The Food and Drug Administration (FDA or we) is extending the comment period for the notice of availability, published in the Federal Register of May 4, 2016 (81 FR 26805),
announcing the draft guidance for industry entitled “Chronic Hepatitis C
Virus Infection: Developing Direct-Acting Antiviral Drugs for
Treatment.” We are taking this action due to maintenance on the Federal
eRulemaking portal from July 1 through July 5, 2016.
Please visit SoulofHealing.org, non profit, 501(c)(3) for our patient assistance programs. If you have been denied by insurance or you do not have insurance please visit SunnyPharma.info to get generic Sovaldi($695), Harvoni($1495), Epclusa($2195) and Daklinza($695). All prices are based upon 12 weeks and 84 tablets. Verified by American doctors and nurses.
No comments:
Post a Comment